Literature DB >> 12804059

Tolerance of ocular iontophoresis in healthy volunteers.

Thomas M Parkinson1, Elizabeth Ferguson, Salvatore Febbraro, Arash Bakhtyari, Martin King, Mohan Mundasad.   

Abstract

To evaluate ocular tolerance, healthy volunteers were iontophoresed transclerally using novel OcuPhor trade mark hydrogel drug delivery applicators filled with balanced salt solution. In this three-period crossover study in 24 male and female subjects, 16 subjects received 0 mA and two of the following DC currents: 0.1, 0.5., 1.0, 2.0, 3.0, or 4.0 mA for 20 min; 6 subjects received 3 mA for 20 min and 1.5 mA for 40 min (both equivalent to 60 mAmin total charge). Safety and tolerance were determined by subjective VAS and objective ophthalmic assessments. Subjects were evaluated before and up to 22 hr after dosing. The applicators were well-tolerated and no clinically significant changes in symptomology or in ophthalmic assessments were seen following exposure to 0-3.0 mA for 20 min or 1.5 mA for 40 min. At 4.0 mA 2 of 4 subjects reported a burning sensation under the applicator during dosing which resolved by 22 hr post-dose; superficial changes in fluorescein staining were observed at 1 hr, but not at 22 hr. The OcuPhor trade mark system has promise for noninvasive drug delivery to the eye.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804059     DOI: 10.1089/108076803321637672

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  18 in total

Review 1.  New techniques for drug delivery to the posterior eye segment.

Authors:  Esther Eljarrat-Binstock; Jacob Pe'er; Abraham J Domb
Journal:  Pharm Res       Date:  2010-02-13       Impact factor: 4.200

2.  Early effects of corneal collagen cross-linking by iontophoresis in ex vivo human corneas.

Authors:  Rita Mencucci; Stefano Ambrosini; Iacopo Paladini; Eleonora Favuzza; Carlotta Boccalini; Giulia Raugei; Gabriella Barbara Vannelli; Mirca Marini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-04       Impact factor: 3.117

3.  Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules.

Authors:  Sarah Molokhia; Kongnara Papangkorn; Charlotte Butler; John W Higuchi; Balbir Brar; Balamurali Ambati; S Kevin Li; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2020-03-05       Impact factor: 2.671

4.  Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.

Authors:  S Kevin Li; Mark R Liddell; He Wen
Journal:  J Pharm Biomed Anal       Date:  2011-01-05       Impact factor: 3.935

5.  Examination of barriers and barrier alteration in transscleral iontophoresis.

Authors:  Sarah A Molokhia; Eun-Kee Jeong; William I Higuchi; S Kevin Li
Journal:  J Pharm Sci       Date:  2008-02       Impact factor: 3.534

6.  International patenting in ophthalmology: An analysis of its structure and relevance for the development of drugs and diagnostics.

Authors:  Hermann A M Mucke; Peter Mucke; Eva Mucke
Journal:  Clin Ophthalmol       Date:  2009-06-02

7.  Influence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-11-13       Impact factor: 3.534

Review 8.  Biomedical applications of electrical stimulation.

Authors:  Siwei Zhao; Abijeet Singh Mehta; Min Zhao
Journal:  Cell Mol Life Sci       Date:  2020-01-23       Impact factor: 9.261

9.  Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration.

Authors:  Eric H Souied; Silvia N M Reid; Natik I Piri; Leonid E Lerner; Steven Nusinowitz; Debora B Farber
Journal:  Exp Eye Res       Date:  2008-04-29       Impact factor: 3.467

Review 10.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.